Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-normal”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Testing effectiveness (Phase 2)Study completedNCT00194714
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Who this might be right for
HER2/Neu PositiveHLA-A2 Positive Cells PresentStage IV Breast Cancer+1 more
University of Washington 22
Not applicableUnknownNCT02852096
What this trial is testing

Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks

Who this might be right for
Gastric CancerHER-2
Shanghai Zhongshan Hospital 600
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Testing effectiveness (Phase 2)UnknownNCT04742153
What this trial is testing

MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc. 66
Not applicableStudy completedNCT01935739
What this trial is testing

Discordant HER2/Neu Status of Breast Cancer.

Who this might be right for
Malignant Neoplasm of Breast.
National Cancer Institute, Thailand 105
Early research (Phase 1)Ended earlyNCT03429101
What this trial is testing

Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Spectrum Pharmaceuticals, Inc 6
Post-approval studies (Phase 4)UnknownNCT05131841
What this trial is testing

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 60
Not applicableNot Yet RecruitingNCT07406594
What this trial is testing

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast Cancer
University of Vermont Medical Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742
What this trial is testing

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 245
Testing effectiveness (Phase 2)Looking for participantsNCT07492394
What this trial is testing

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 60
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT02273973
What this trial is testing

Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Who this might be right for
Breast Cancer
Genentech, Inc. 334
Testing effectiveness (Phase 2)Study completedNCT00191373
What this trial is testing

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Who this might be right for
Breast NeoplasmsCancer of the BreastBreast Cancer
Eli Lilly and Company 66
Large-scale testing (Phase 3)Looking for participantsNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Post-approval studies (Phase 4)Looking for participantsNCT06641544
What this trial is testing

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Not applicableStudy completedNCT02521363
What this trial is testing

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 11
Next Page